Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTZCRP3)

DTT Name ERK activator kinase (MEK)
Synonyms MEK; MAPKK; MAP kinase kinase
Gene Name NO-GeName
DTT Type
Successful target
 [1]
Related Disease
Melanoma [ICD-11: 2C30]
UniProt ID
NOUNIPROTAC
TTD ID
T99031

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arry-162 DM1P6FR Melanoma 2C30 Approved [1]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
HL-085 DMJDVCW Melanoma 2C30 Phase 1/2 [2]
BI 3011441 DMFJGUL Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
GDC-0623 DMDY08K Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
------------------------------------------------------------------------------------
13 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azetidine derivative 2 DMTB3KS N. A. N. A. Patented [6]
Benzoheterocyclic compound 1 DM3K25J N. A. N. A. Patented [6]
Benzoimidazole derivative 1 DMUJFCK N. A. N. A. Patented [6]
Benzoimidazole derivative 2 DMHX5VO N. A. N. A. Patented [6]
N-(arylamino)sulfonamide derivative 1 DM8GJA7 N. A. N. A. Patented [6]
P-toluenesulfonate derivative 1 DME57SJ N. A. N. A. Patented [6]
PMID28594589-Compound-TABLE3C1 DMLZV70 N. A. N. A. Patented [6]
PMID28594589-Compound-TABLE3C12 DMPK7IU N. A. N. A. Patented [6]
PMID28594589-Compound-TABLE3C14 DM4KWVF N. A. N. A. Patented [6]
PMID28594589-Compound-TABLE3C2 DMVYG0U N. A. N. A. Patented [6]
Pyridinone compound 1 DM2GR5Q N. A. N. A. Patented [6]
Pyridopyrimidine derivative 1 DMTZK6V N. A. N. A. Patented [6]
Quinazolines and azaquinazoline derivative 1 DME24BI N. A. N. A. Patented [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Patented Agent(s)

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
3 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
4 Clinical pipeline report, company report or official report of Genentech (2011).
5 Clinical pipeline report, company report or official report of Roche.
6 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.